Richter Revenue Growth in Line with Expectations

The Hungarian pharma company Gedeon Richter Plc.'s consolidated sales revenue for the first half of the year was HUF 465.5 billion, 10.9% higher than a year earlier, the company announced on the Budapest Stock Exchange (BÉT) website on Wednesday.

Net profit for the first half of 2025 was HUF 120 billion, which is 13% lower than the previous year due to the lack of exchange rate gains, despite higher operating results, the company said.

CEO Gábor Orbán highlighted in the report that “women’s Healthcare shifted gears, Vraylar continued to enjoy strong demand growth, and Biotech losses narrowed in the last quarter. With a robust Q2, we are now tracking in line with our annual guidance despite the strong base. Our innovative pillar has seen important progress lately: in Neuroscience, a second phase 2 clinical trial (in GAD) was initiated in the AbbVie-partnered program,
RGH-932, thus two parallel phase 2 studies are running now, while preclinical projects also are moving forward according to plan. The Granata Bio partnership marks an important step in establishing our presence in the US fertility market, which, coupled with the strong momentum in menopause, endometriosis and fertility more broadly, makes us confident that we are on the right track in executing our strategy.“

The forecast remains unchanged: this year, they expect growth of around 10% in both revenue and adjusted EBIT (earnings before interest and taxes), excluding currency effects.

Pharmaceutical sales grew in almost all regions, up 11% to HUF 458 billion, with an 8% increase excluding currency effects.